Equities

Bachem Holding AG

Bachem Holding AG

Actions
  • Price (EUR)23.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 28 2019 12:30 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.

  • Revenue in CHF (TTM)498.98m
  • Net income in CHF98.17m
  • Incorporated1971
  • Employees1.66k
  • Location
    Bachem Holding AGHauptstrasse 144BUBENDORF 4416SwitzerlandCHE
  • Phone+41 619352333
  • Fax+41 619352324
  • Websitehttp://www.bachem.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.